Physician profile
Sarah E Ensinger
NPI 1720338049
$3,574.31
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,096 · 2022: $1,485 · 2023: $994.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $932 · Education: $61.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $932.08 |
| Education | $61.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,385.54 | 2021-2023 | Trelegy Ellipta, Nucala, Shingrix |
| Astrazeneca Pharmaceuticals LP | $464.43 | 2021-2023 | Tezspire, Fasenra |
| Genzyme Corporation | $348.71 | 2021-2023 | |
| Teva Pharmaceuticals USA, INC. | $287.75 | 2021-2023 | |
| Regeneron Healthcare Solutions, INC. | $219.35 | 2021-2023 | Dupixent |
| Csl Behring | $206.60 | 2021-2023 | Haegarda |
| Kaleo, INC. | $183.37 | 2021-2023 | Auvi-Q |
| Optinose US, INC. | $124.60 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.95 | 2021-2022 | |
| Amgen INC. | $78.44 | 2022-2023 | Tezspire |
| Sanofi-Aventis U.S. LLC | $61.99 | 2023 | |
| Pfizer INC. | $46.54 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $33.98 | 2021 | |
| Eyevance Pharmaceuticals LLC | $24.82 | 2021 | |
| Biocryst US Sales Co., LLC | $19.24 | 2023 | Orladeyo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Ensinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.